Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

ClinicalTrials.gov ID: NCT06252649

Public ClinicalTrials.gov record NCT06252649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Study identification

NCT ID: NCT06252649
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Amgen; Industry
Enrollment: 450 participants

Conditions and interventions

Conditions

Metastatic Colorectal Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 16, 2024
Primary completion: Sep 24, 2028
Completion: Apr 24, 2032
Last update posted: Aug 20, 2026

2024 – 2032

United States locations

U.S. sites: 26
U.S. states: 14
U.S. cities: 24

Facility	City	State	ZIP	Site status
Ironwood Cancer and Research Centers Scottsdale	Chandler	Arizona	85224	Recruiting
Providence Saint Jude Medical Center	Fullerton	California	92835	Terminated
City of Hope National Medical Center	Long Beach	California	90813	Recruiting
Cancer and Blood Research Center, LLC	Los Alamitos	California	90720	Recruiting
California Research Institute	Los Angeles	California	90027	Terminated
Norwalk Hospital	Norwalk	Connecticut	06856	Terminated
Cancer Specialists of North Florida - Southpoint	Jacksonville	Florida	32256	Recruiting
D and H Cancer Research Center	Margate	Florida	33063	Terminated
Mid Florida Hematology and Oncology Centers PA	Orange City	Florida	32763	Terminated
Boca Raton Clinical Research Medical Center Inc	Plantation	Florida	33322	Terminated
Georgia Cancer Specialists	Atlanta	Georgia	30342	Terminated
Insight Research Institute	Chicago	Illinois	60616	Recruiting
Hope and Healing Cancer Services	Hinsdale	Illinois	60521	Terminated
Orchard Healthcare Research Inc	Skokie	Illinois	60076	Terminated
Pikeville Medical Center	Pikeville	Kentucky	41501	Recruiting
Henry Ford Health System	Detroit	Michigan	48202	Terminated
Cancer and Hematology Centers of Western Michigan	Grand Rapids	Michigan	49503	Recruiting
Saint Louis Cancer Care West County	Bridgeton	Missouri	63044	Terminated
Minniti Center for Medical Oncology and Hematology	Mickleton	New Jersey	08056	Terminated
Duke Cancer Center	Durham	North Carolina	27710	Recruiting
FirstHealth Cancer Center	Pinehurst	North Carolina	28374	Terminated
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	Terminated
Carolina Blood and Cancer Care	Rock Hill	South Carolina	29732	Terminated
Tennessee Oncology PLLC - Chattanooga	Nashville	Tennessee	37203	Recruiting
Tennessee Oncology, PLLC	Nashville	Tennessee	37203	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 265 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06252649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06252649 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →